SARS-CoV-2 3CLpro-IN-41
SARS-CoV-2 3CLpro-IN-41 is a SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.83 μM. SARS-CoV-2 3CLpro-IN-41 irreversibly covalently binds to Cys145 in the catalytic center of SARS-CoV-2 3CLpro, thereby blocking polyprotein cleavage to inhibit viral replication. SARS-CoV-2 3CLpro-IN-41 can be used for research on SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- Formula: C14H10F3NO4
- Molecular Weight:313.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
79.87 μM
|
Cytotoxicity against human A549-hACE2-TMPRSS2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 2 μM elacridar by CCK-8 assay.
Cytotoxicity against human A549-hACE2-TMPRSS2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 2 μM elacridar by CCK-8 assay.
|
42642712 |
| A549 | IC50 |
15.03 μM
|
Antiviral activity against wild-type SARS-CoV-2 in human A549-hACE2-TMPRSS2 cells assessed as inhibition of viral replication measured after 24 hrs by immunofluorescence assay.
Antiviral activity against wild-type SARS-CoV-2 in human A549-hACE2-TMPRSS2 cells assessed as inhibition of viral replication measured after 24 hrs by immunofluorescence assay.
|
42642712 |
In Vitro
SARS-CoV-2 3CLpro-IN-41 (compound B2) (25 μM; 24 h) exhibits potent antiviral activity against SARS-CoV-2 in A549-hACE2-TMPRSS2 cells, almost completely inhibiting viral replication at 25 μM[1].
SARS-CoV-2 3CLpro-IN-41 (24 h) exhibits low cytotoxicity (CC50 = 79.87 μM) and potent antiviral activity (EC50 = 15.03 μM) in A549-hACE2-TMPRSS2 cells[1].
SARS-CoV-2 3CLpro-IN-41 (60 min) exhibits an in vitro enzymatic inhibition IC50 of 0.83 μM against SARS-CoV-2 3CLpro[1].
SARS-CoV-2 3CLpro-IN-41 (5-60 min) exhibits time-dependent inhibition of SARS-CoV-2 3CLpro, with IC50 values decreasing from 7.35 μM at 5 min to 0.83 μM at 60 min[1].
SARS-CoV-2 3CLpro-IN-41 acts as a covalent inhibitor of SARS-CoV-2 3CLpro with a Ki of 2.11 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549-hACE2-TMPRSS2 cells
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Nearly completely suppressed viral replication at 25 μM.
Chemical Information
-
Molecular Weight 313.23
-
Formula C14H10F3NO4
-
SMILES
O=C(NC1=CC=C(O)C(O)=C1)C2=CC=C(OC(F)(F)F)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)